APFED Announces 2023 AAAAI/APFED Best Abstract on EGIDs Awards

Two recipients are recognized for best-scoring abstracts focused on eosinophilic gastrointestinal diseases (EGIDs)

ATLANTA, GA —The American Partnership for Eosinophilic Disorders (APFED) has announced the recipients of the 2023 AAAAI/APFED Best Abstract on EGIDs Awards for research presented during the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio on February 24-27, 2023.

The 2023 AAAAI/APFED Best Abstract on EGIDs recipients are Jonathan M. Spergel, MD, PhD, Children’s Hospital of Philadelphia, for his abstract entitled, “Dupilumab improves type 2 comorbidity outcomes in patients with eosinophilic esophagitis and comorbid disease at baseline: from Parts A and B of LIBERTY-EoE-TREET” and Victoria T. Nguyen, DO, Penn State College of Medicine, for her abstract entitled, “Major depression and Suicide: A Common Comorbidity of Eosinophilic Esophagitis.”

The AAAAI/APFED Best Abstract on EGIDs Awards honor outstanding research abstracts on eosinophil-associated gastrointestinal diseases (EGIDs).  APFED funds the $750 awards to help enable researchers travel to present their findings more broadly to their peers. Abstract award winners may go on to successfully compete for grants from APFED or from other funding mechanisms.

The awards were made possible thanks to the generous donations to APFED’s HOPE on the Horizon Research Program. For more information or to make a donation, visit apfed.org.